Aandelen in “Farmaceutica”

Aandeel Datum Koers Evolutie
Even geduld...

Nieuws over “Farmaceutica”

17/09 · Novo: CHMP recommends EU approval of FREHEMGO® (denecimig), the first factor VIIIa mimetic offering monthly, once every two weeks and weekly dosing in a pre-filled pen, for the treatment of haemophilia A · Persbericht

17/09 · Novo: CHMP recommends EU approval of FREHEMGO® (denecimig), the first factor VIIIa mimetic offering monthly, once every two weeks and weekly dosing in a pre-filled pen, for the treatment of haemophilia A · Persbericht

17/09 · AbbVie to Present Phase 3 Etentamig Results and Data from Broad Multiple Myeloma Portfolio at the 2026 International Myeloma Society (IMS) Meeting · Persbericht

17/09 · Allergan Aesthetics Presents New Clinical Data Evaluating Skin Quality Improvements in Individuals Taking Medical Weight Loss Medications · Persbericht

16/09 · Novo and Anthropic will collaborate to advance drug discovery with Claude · Persbericht

16/09 · Cardiol Therapeutics Announces Warrant Exercise for Over USD $7 Million in Proceeds · Persbericht

16/09 · Viatris Announces Approval of WAKIX® (Pitolisant) in Japan, a First-in-Class Treatment for Narcolepsy and Excessive Daytime Sleepiness Associated With Obstructive Sleep Apnea Syndrome · Persbericht

16/09 · Novo to share real-world and clinical data including Wegovy® pill, and cardiometabolic pipeline progress with next-generation amylin treatments at EASD 2026 · Persbericht

15/09 · Correction: IPSEN - Buy-back programme - Art 5 of MAR - Week 36- 2026 · Persbericht

15/09 · AbbVie Named Official Pharmaceutical Sponsor of the PGA TOUR and 2026 Presidents Cup, Launches Birdies for Brain Health Campaign · Persbericht

15/09 · Allergan Aesthetics to Advance Scientific Dialogue on Skin Longevity, Aging Biology and Exosome Science at the 2026 Science of Skin Summit · Persbericht

15/09 · Lilly to present new data on Foundayo, retatrutide, and eloraTZP at EASD 2026, as it strives to change the course of cardiometabolic health · Persbericht

15/09 · RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus LAZCLUZE® (lazertinib) with prophylactic strategies shows low rates of treatment-related events at WCLC 2026 · Persbericht

14/09 · IPSEN - Buy-back programme - Art 5 of MAR - Week 37 - 2026 · Persbericht

14/09 · Novo Nordisk kiest voor nieuwe naam om zichtbaarheid op de markt van medicijnen tegen obesitas te vergroten · Business AM

Key takeaways In een poging om zijn zichtbaarheid te vergroten tijdens de escalerende concurrentie op het gebied van medicijnen tegen obesitas, stapt Novo Nordisk A/S over op een vereenvoudigde merkidentiteit en noemt het...

14/09 · Novo Nordisk A/S - share repurchase programme · Persbericht

14/09 · Press Release: Sanofi and Cheplapharm to create new strategic partnership in mature medicines · Persbericht

14/09 · Farmabedrijf Novo Nordisk slankt naam af tot Novo · Tijd.be (€)

Het Deense farmabedrijf Novo Nordisk, bekend van de afslankmedicatie Ozempic en Wegovy, wijzigt zijn naam voor zijn producten en voor dagelijks gebruik in Novo. Dat moet helpen in de felle concurrentiestrijd rond de medicatie.

14/09 · Novo Nordisk enters next chapter to bring better health to more people, supported by ‘Novo’ rebrand and updated corporate culture · Persbericht

14/09 · NANOBIOTIX Announces Complete Full Cohort Phase 1 Results for JNJ-1900 (NBTXR3) in Inoperable, Recurrent Non-Small Cell Lung Cancer · Persbericht

14/09 · Johnson & Johnson's RYBREVANT® (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation-positive lung cancer · Persbericht

Mijn selecties